New Prostate Cancer Biomarkers Can Improve Precision Therapy
Improvements are on the horizon in the treatment of prostate cancer that could improve future therapy.
Study compared radical prostatectomy plus adjuvant EBRT or ADT, or both, with a triple combination of EBRT, brachytherapy, and ADT for Gleason score 9-10 prostate cancer.
Study of men who underwent salvage radical prostatectomy for radiorecurrent prostate cancer found a 10-year rate of biochemical progression-free survival of 33%.
Many patients with extraprostatic extension on biopsy experience biochemical recurrence after surgery and require early multi-modal therapy.